Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand - PubMed (original) (raw)
. 2009 Nov 1;69(21):8516-25.
doi: 10.1158/0008-5472.CAN-09-2522. Epub 2009 Oct 20.
Affiliations
- PMID: 19843856
- DOI: 10.1158/0008-5472.CAN-09-2522
Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand
Hong Sung Kim et al. Cancer Res. 2009.
Abstract
Oncolytic viral vectors have shown promise as antitumor therapeutic agents but their effectiveness is complicated by induction of antiviral antibody responses and rapid host clearance of recombinant vectors. We developed a recombinant oncolytic vaccinia virus expressing the 4-1BBL T-cell costimulatory molecule (rV-4-1BBL) and showed modest tumor regression in the poorly immunogenic B16 murine melanoma model. To improve the therapeutic potential of this vector, we tested the antitumor activity of local intratumoral injection in the setting of host lymphodepletion, which has been shown to augment vaccination and adoptive T-cell therapy. In this model, rV-4-1BBL injection in the setting of lymphodepletion promoted MHC class I expression, reduced antiviral antibody titers, promoted viral persistence, and rescued effector-memory CD8(+) T cells, significantly improving the therapeutic effectiveness of the oncolytic vector. These data suggest that vaccination with rV-4-1BBL in the setting of host nonmyeloablative lymphodepletion represents a logical strategy for improving oncolytic vaccination in melanoma, and perhaps other cancers as well.
Similar articles
- Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ, Kim JH, Lee YS, Kim J, Suh BS, Kim H, Cho S, Sohn JH, Kim GE, Yun CO. Choi KJ, et al. Gene Ther. 2006 Jul;13(13):1010-20. doi: 10.1038/sj.gt.3302759. Epub 2006 Mar 9. Gene Ther. 2006. PMID: 16525479 - Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
Lee YS, Kim JH, Choi KJ, Choi IK, Kim H, Cho S, Cho BC, Yun CO. Lee YS, et al. Clin Cancer Res. 2006 Oct 1;12(19):5859-68. doi: 10.1158/1078-0432.CCR-06-0935. Clin Cancer Res. 2006. PMID: 17020994 - Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.
Diaz RM, Galivo F, Kottke T, Wongthida P, Qiao J, Thompson J, Valdes M, Barber G, Vile RG. Diaz RM, et al. Cancer Res. 2007 Mar 15;67(6):2840-8. doi: 10.1158/0008-5472.CAN-06-3974. Cancer Res. 2007. PMID: 17363607 - [Oncolytic virus therapy for malignant brain tumors].
Ino Y, Todo T. Ino Y, et al. Brain Nerve. 2009 Jul;61(7):815-22. Brain Nerve. 2009. PMID: 19618859 Review. Japanese. - Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways.
Naik S, Russell SJ. Naik S, et al. Expert Opin Biol Ther. 2009 Sep;9(9):1163-76. doi: 10.1517/14712590903170653. Expert Opin Biol Ther. 2009. PMID: 19637971 Review.
Cited by
- Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth.
Ramos-Gonzalez MR, Tarique M, Batra L, Arguc F, Garza-Morales R, Shirwan H, Yolcu ES, Gomez-Gutierrez JG. Ramos-Gonzalez MR, et al. Vaccines (Basel). 2024 Mar 21;12(3):340. doi: 10.3390/vaccines12030340. Vaccines (Basel). 2024. PMID: 38543974 Free PMC article. - Personalizing Oncolytic Immunovirotherapy Approaches.
Stergiopoulos GM, Iankov I, Galanis E. Stergiopoulos GM, et al. Mol Diagn Ther. 2024 Mar;28(2):153-168. doi: 10.1007/s40291-023-00689-4. Epub 2023 Dec 27. Mol Diagn Ther. 2024. PMID: 38150172 - An oncolytic virus-delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment.
DePeaux K, Rivadeneira DB, Lontos K, Dean VG, Gunn WG, Watson MJ, Yao T, Wilfahrt D, Hinck C, Wieteska L, Thorne SH, Hinck AP, Delgoffe GM. DePeaux K, et al. J Exp Med. 2023 Oct 2;220(10):e20230053. doi: 10.1084/jem.20230053. Epub 2023 Aug 8. J Exp Med. 2023. PMID: 37552475 Free PMC article. - Current strategies in engaging oncolytic viruses with antitumor immunity.
Boagni DA, Ravirala D, Zhang SX. Boagni DA, et al. Mol Ther Oncolytics. 2021 May 14;22:98-113. doi: 10.1016/j.omto.2021.05.002. eCollection 2021 Sep 24. Mol Ther Oncolytics. 2021. PMID: 34514092 Free PMC article. Review. - Engineering Oncolytic Vaccinia Virus to redirect Macrophages to Tumor Cells.
Cao F, Nguyen P, Hong B, DeRenzo C, Rainusso NC, Rodriguez Cruz T, Wu MF, Liu H, Song XT, Suzuki M, Wang LL, Yustein JT, Gottschalk S. Cao F, et al. Adv Cell Gene Ther. 2021 Apr;4(2):e99. doi: 10.1002/acg2.99. Epub 2020 Jul 3. Adv Cell Gene Ther. 2021. PMID: 33829146 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials